{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:53:02Z","timestamp":1791175982586,"version":"4.1.0"},"reference-count":4,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2026.2002791","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:32:33Z","timestamp":1791174753000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Editorial: Evolving non-invasive biomarkers: chemokines and multi-omic profiling in NSCLC immunotherapy response"],"prefix":"10.3389","volume":"16","author":[{"given":"Jacobo","family":"Rogado","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Hospital Universitario de La Princesa","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabet","family":"Gonz\u00e1lez del Portillo","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Hospital Universitario Rey Juan Carlos","place":["M\u00f3stoles, Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Casado El\u00eda","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital General de Villalba","place":["Collado Villalba, Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Rubio-Perez","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center","place":["New York, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801946","article-title":"Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden","volume":"378","author":"Hellmann","year":"2018","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14122898","article-title":"Peripheral blood mononuclear cells predict therapeutic efficacy of immunotherapy in NSCLC","volume":"14","author":"Rogado","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-024-03828-3","article-title":"The role of the CXCL12\/CXCR4 axis in the immunotherapy of non-small cell lung cancer","volume":"27","author":"Rogado","year":"2025","journal-title":"Clin Transl Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.2002791\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:32:46Z","timestamp":1791174766000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.2002791\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,5]]},"references-count":4,"alternative-id":["10.3389\/fonc.2026.2002791"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.2002791","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,5]]},"article-number":"2002791"}}